These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 28506743)

  • 1. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
    David A
    Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotherapy Targeting the Tumor Microenvironment.
    Gong BS; Wang R; Xu HX; Miao MY; Yao ZZ
    Curr Cancer Drug Targets; 2019; 19(7):525-533. PubMed ID: 30569855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide ligand-mediated targeted drug delivery of nanomedicines.
    Jiang Z; Guan J; Qian J; Zhan C
    Biomater Sci; 2019 Jan; 7(2):461-471. PubMed ID: 30656305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating angiogenesis with integrin-targeted nanomedicines.
    Duro-Castano A; Gallon E; Decker C; Vicent MJ
    Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.
    Kebebe D; Liu Y; Wu Y; Vilakhamxay M; Liu Z; Li J
    Int J Nanomedicine; 2018; 13():1425-1442. PubMed ID: 29563797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-decorated polymeric nanomedicines for precision cancer therapy.
    Sun H; Dong Y; Feijen J; Zhong Z
    J Control Release; 2018 Nov; 290():11-27. PubMed ID: 30290243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Targeting of Cancers with Nanotherapeutics.
    Foster C; Watson A; Kaplinsky J; Kamaly N
    Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
    Muntimadugu E; Kommineni N; Khan W
    Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
    Zhang B; Shi W; Jiang T; Wang L; Mei H; Lu H; Hu Y; Pang Z
    Oncotarget; 2016 Sep; 7(38):62607-62618. PubMed ID: 27566585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
    Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
    Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma homing peptide-modified PEG-PCL nanoparticles for enhanced anti-glioma therapy.
    Chi Y; Zhu S; Wang C; Zhou L; Zhang L; Li Z; Dai Y
    J Drug Target; 2016; 24(3):224-32. PubMed ID: 26219518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.